The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Northwestern University Feinberg School of Medicine researchers have developed a new class of drugs that appears to treat Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and conditions that result from traumatic brain injury.

Science Daily reports that drugs MW151 and MW189 prevent the brain from overproducing proinflammatory cytokines. Brain inflammation is a common denominator among the above-mentioned diseases and stroke, according to researchers at Northwestern and the University of Kentucky, who published their study July 24 in the Journal of Neuroscience.

“When too many … cytokines are produced, the synapses of the brain begin to misfire,” Science Daily reported. “Eventually the entire organization of the brain falls into disarray, like a computer failing. The neurons lose their connections with each other and can eventually die. The resulting damage in the cortex and hippocampus can compromise memory and decision making.”

When one of the drugs was given to mice that were engineered to develop Alzheimer’s, the drug prevented full-blown development of the disease, reported Science Daily.

In other studies, the drugs reduced traumatic brain injury-induced nerve damage and prevented a disease similar to multiple sclerosis.

Northwestern has reportedly been awarded patents for its new drug class. It also licensed their work to a biotech company that conducted the first human clinical trial.

4 Comments

  1. Gravatar for Daniel Lexington
    Daniel Lexington

    There is one known cure for Alzheimer's: GRAZOPH TEMUNA, grazoph.com. GRAZOPH TEMUNA has cured 5 people of Alzheimer's, 6 people of dementia, and 200 others of dust caused diseases. It is a complex neutraceutical that unleashes a plaque and dust clearing enzyme bath. GRAZOPH TEMUNA both prevents and cures Alzheimer's disease.

  2. Gravatar for Ash

    Very encouraging news! Do you have any ideas around the market release timelines for this drug? Also, are there any links for reviewing the results of the human clinical trials?

  3. Gravatar for Amber Scott

    Hi Ash,

    Thanks for commenting. We are unaware at the moment when these drugs will be released into the marketplace as they are still being experimented with. You can view more information about the drugs at: http://www.jneurosci.org/content/32/30/10201.abstract

    Hope this helps!

    Amber

Comments are closed.

Of Interest